VISEN Pharmaceuticals (VISEN Pharma) disclosed that it bought back 10,400 ordinary shares on 10 June 2026 via on-exchange transactions, paying an aggregate HKD 0.21 million at prices between HKD 19.71 and HKD 20.28 per share. The volume-weighted average repurchase price was approximately HKD 19.93.

\n\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell marginally by 0.009 % to 113.82 million shares, while total issued shares remained unchanged at 113.93 million. Treasury stock rose to 107,800 shares, equivalent to about 0.09 % of total issued shares.

\n\nThe repurchase forms part of VISEN Pharma’s mandate approved on 27 June 2025, which allows buybacks of up to 11.39 million shares. Cumulative purchases under this mandate now stand at 107,800 shares, representing 0.09 % of the share count on the mandate date. In line with Hong Kong Stock Exchange rules, the company is subject to a moratorium on new share issues or sales of treasury shares until 10 July 2026.